NasdaqCM - Nasdaq Real Time Price USD

MoonLake Immunotherapeutics (MLTX)

37.62

-0.04

(-0.11%)

At close: May 16 at 4:00:00 PM EDT

37.62

0.00

(0.00%)

After hours: May 16 at 4:05:08 PM EDT

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks yesterday

MLTX
-0.11%
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in H

GlobeNewswire 4 days ago

MLTX
-0.11%
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates. The webcast, streamed live from New

GlobeNewswire 21 days ago

MLTX
-0.11%
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President […]

Insider Monkey 23 days ago

MLTX
-0.11%
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a new standard for the quantum of a nondilutive facility for a development-stage therapeutics company.Facility adds to the $448 million cash position disclosed in previously filed 10-K and provides funding for the next steps of the Company’s growth

GlobeNewswire last month

MLTX
-0.11%
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phas

GlobeNewswire 2 months ago

MLTX
-0.11%
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the market, […]

Insider Monkey 2 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field, Head of European Pharma Research at Barclays, […]

Insider Monkey 2 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising in […]

Insider Monkey 2 months ago

MLTX
-0.11%
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm expects sonelokimab’s “differentiating features to translate to best-in-class efficacy in axial spondyloarthritis, palmoplantar pustulosis, and hidradenitis suppurativa. These are severe diseases with high unmet need, the analyst tells investors in a research note. BTIG says the axial spondyloarthritis market is expected to exceed $10B by the mid-2030s and note

TipRanks 4 months ago

MLTX
-0.11%
MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MoonLake Immunotherapeutics' (MLTX) three new studies of the company's nanobody sonelokimab in three

PREMIUM
MT Newswires 4 months ago

MLTX
-0.11%
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpAPhase 2 and Phase 3 data read-outs across all target i

GlobeNewswire 4 months ago

MLTX
-0.11%
Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

Key Insights MoonLake Immunotherapeutics' estimated fair value is US$73.93 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 4 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2)Program will evaluate sonelokimab for a total of 52 weeks, across IZAR-1 and IZAR-2, a

GlobeNewswire 5 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical p

GlobeNewswire 6 months ago

MLTX
-0.11%
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics

On October 4, 2024, Biotechnology Value Fund L.P. executed a significant transaction involving the shares of MoonLake Immunotherapeutics (NASDAQ:MLTX). Following this transaction, Biotechnology Value Fund L.P. now holds a total of 19,751,284 shares in MoonLake Immunotherapeutics, representing 31.40% of their total portfolio.

GuruFocus.com 7 months ago

MLTX
-0.11%
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) ranks among the best guru stocks to buy now. Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking […]

Insider Monkey 7 months ago

MLTX
-0.11%

^GSPC
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

We recently compiled a list of the 10 Worst ADR Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other ADR stocks. An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a […]

Insider Monkey 7 months ago

MLTX
-0.11%
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will provide business u

GlobeNewswire 8 months ago

MLTX
-0.11%

Performance Overview

Return	MLTX	S&P 500 (^GSPC)
YTD	-30.53%	+1.30%
1-Year	-7.93%	+12.48%
3-Year	+702.13%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MoonLake Immunotherapeutics (MLTX)

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Performance Overview